113 HR 413 IH: To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012. U.S. House of Representatives 2013-01-23 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I 113th CONGRESS 1st Session H. R. 413 IN THE HOUSE OF REPRESENTATIVES January 23, 2013 Mr. Welch (for himself, Mr. Hanna, Mr. Cooper, and Mr. Braley of Iowa) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

1.

Eliminating the 2-year delay in implementation of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system

Section 632(b) of the American Taxpayer Relief Act of 2012 (Public Law 112–240) is amended by striking all that precedes With respect to the implementation and inserting the following:: (b)

Monitoring of implementation of oral-Only ESRD-Related drugs in the ESRD prospective payment system

With respect to the implementation .